Skip to content
15% off your first order15% off your first order

Tirzepatide 40 mg pre-filled pen

Dual-agonist weight research

Investigated for combined GIP and GLP-1 signaling.

$239.95CAD· $6.00/mg
Format. Vial or pen?
1
  • Ships from Canada in 1–2 business days
  • Free shipping over $120
  • Place your order, then send the e-Transfer. We pack it as soon as it arrives.

For research use only. Not for human consumption.

Complete your setup

Pre-filled, with 4 pen needles in the box. Just add wipes.

Compare. Side by side, from the research.

About Tirzepatide

Tirzepatide is studied as a dual agonist at the GIP and GLP-1 receptors. Research examines whether combining the two incretin pathways differs from GLP-1 agonism alone.

How it works

Dual Incretin
Studied at both GIP and GLP-1 receptors, the GIP component distinguishing it from single agonists.
Metabolic Signaling
Explored for effects across glucose handling and appetite regulation together.
Read the full research

What you need

  • Alcohol Wipes
  • A protocol guide comes with every order

Shipping & payment

  • Packed and dispatched within 1–2 business days
  • Delivered across Canada in 2–5 business days, tracked
  • Temperature-controlled packaging where the product needs it
  • Free shipping on orders over $120
  • Prices in CAD · pay by Interac e-Transfer
Format
Disposable pre-filled pen · 4 pen needles included
Strength
40 mg per pre-filled pen
Storage
Refrigerate, away from light.
Route in research
Subcutaneous
Target
GLP-1R / GIPR
SKU
TR40DSP
Purity
High-performance liquid chromatography (HPLC), by an independent laboratory
Identity
Mass spectrometry, on the same batch
How often
Every batch
COA
The certificate of analysis is matched to the lot code printed on your vial
Evidence
Late clinical

Check your lot

Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.

Late clinicalTirzepatide has been evaluated in multiple randomized phase 3 trials, including SURPASS-1, SURPASS-2 against semaglutide, and SURMOUNT-4, with phase 2 work in liver disease and a cardiovascular outcomes trial also underway.

What research examines

  • Glycemic control in type 2 diabetes trials
  • Weight reduction and weight maintenance in adults with obesity
  • Appetite, energy intake, and fat mass
  • Head-to-head comparison with semaglutide
  • Metabolic dysfunction-associated steatohepatitis with liver fibrosis
  • Cardiovascular outcomes compared with dulaglutide

Reported in studies

  • Safety was a primary focus of phase 3 trials such as SURPASS-1, though specific adverse event rates are not summarized here
  • Cardiovascular safety is being assessed against dulaglutide in the SURPASS-CVOT trial
  • Studied for effects on gastric emptying as part of its mechanism
  • Long-term safety outside controlled trial settings is not characterized in this overview
Read the full research page· 5 cited studies

Published research protocols

2.5 mg, 1/week, am fasted

Research protocols have used 1.5–15 mg per administration, once weekly (morning, fasted), stepping up from 2.5 mg to 10 mg by week 13. Reported cycle: continuous until target weight loss.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

CoreX AI

Ask about Tirzepatide

Plain answers, from the basics to the studies.

Research information, not medical advice.

Often researched with Tirzepatide

FAQ

Questions, answered

  • Tirzepatide is a peptide studied as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Research examines whether engaging both incretin pathways produces effects that differ from GLP-1 agonism alone. It has been evaluated in large randomized clinical trials in type 2 diabetes and obesity, and in smaller trials exploring liver disease and cardiovascular outcomes.

  • Tirzepatide is studied at both the GIP and GLP-1 receptors, and its GIP activity distinguishes it from single-receptor GLP-1 agonists. Research has explored its combined effects on insulin signaling, gastric emptying, and satiety. Mechanistic work published in JCI Insight described it as an imbalanced and biased dual agonist, meaning its activity at the two receptors and their downstream signaling pathways is not equivalent.

  • Phase 3 trials have examined glycemic control in type 2 diabetes, including SURPASS-1 and a head-to-head comparison with semaglutide. The SURMOUNT-4 trial studied continued use for maintenance of weight reduction in adults with obesity, and a later trial compared it with semaglutide for obesity. Other studies have examined appetite, energy intake, and fat mass, liver fibrosis in steatohepatitis, and cardiovascular events versus dulaglutide.

  • Safety was assessed alongside efficacy in phase 3 trials such as SURPASS-1, and cardiovascular safety is being evaluated against dulaglutide in the SURPASS-CVOT trial. Specific adverse event types and rates are not summarized in this overview. Because the compound acts on gastric emptying as part of its studied mechanism, gastrointestinal effects are an area of research attention. Researchers should consult the primary trial publications for detailed safety findings.

  • Research protocols have used 1.5 to 15 mg per administration, given subcutaneously once weekly (morning, fasted), stepping up from 2.5 mg to 10 mg by week 13. The reported cycle was continuous until target weight loss. These figures describe what published protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.

Vial · Pen

Triple-agonist weight research

GLP-3R · 4 sizes

$119/ 10 mg vial